Survey: Compliance Programs Don’t Hurt Bottom Line, But Face Other Hurdles
This article was originally published in The Gray Sheet
Executive Summary
Nine out of 10 device and diagnostic firms responding to a survey say implementing a compliance program based on the 1AdvaMed Code of Ethics did not hurt their company's bottom line, including 10% who say their compliance program increased revenueYou may also be interested in...
Waxman’s Oversight Committee Looks Into Drug-Eluting Stents
The House Committee on Oversight and Government Reform is requesting information on the off-label use and marketing of drug-eluting stents
Device Firms Are Adopting And Promoting Ethics Standards, Survey Finds
A new survey suggests that medical device firms are complying with industry standards written to prevent fraudulent sales and marketing practices. Roughly 75% of surveyed companies said they post their compliance programs on the company website
Unilever Hit With Class Action Over Mercury-Laced Pond’s Cream Originating In Mexico
According to the plaintiff, Unilever’s Pond’s Rejuveness Anti-Wrinkle Cream is defective insofar as tested product has been found to contain unlabeled mercury, constituting negligence that has resulted in user injuries. The plaintiff seeks certification of a transnational class and compensatory and punitive damages, among other relief.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: